18 -2 (52) 2023 — Talipova Yu.Sh., Tulaboeva G.M. — PREDICTION OF THE RISK OF FATAL COMPLICATIONS IN ELDERLY PATIENTS WHO SURVIVED COVID-19

PREDICTION OF THE RISK OF FATAL COMPLICATIONS IN ELDERLY PATIENTS WHO SURVIVED COVID-19

Talipova Yu.Sh., Center for the Development of Professional Qualifications of Medical Workers, Department of Cardiology and gerontology with a course of interventional cardiology and arrhythmology

Tulaboeva G.M., Center for the Development of Professional Qualifications of Medical Workers, Department of Cardiology and gerontology with a course of interventional cardiology and arrhythmology

Sagatova Kh.M. Center for the Development of Professional Qualifications of Medical Workers, Department of Cardiology and gerontology with a course of interventional cardiology and arrhythmology

Abdukadirova N.M., Center for the Development of Professional Qualifications of Medical Workers, Department of Cardiology and gerontology with a course of interventional cardiology and arrhythmology

Khashimov A.A., Ferghana Regional Multidisciplinary Medical Center

Achilov F.K. District medical Association of Kogon

Resume

Relevance. A new coronavirus infection can provoke acute myocardial injury and other new cardiac complications.

Since a number of drugs used in COVID-19 have cardiotoxic effects, constant monitoring of hemodynamic parameters. Viral infection can destabilize the state of the cardiovascular system, which significantly increases the risk of mortality in concomitant cardiovascular diseases (CVD).

Purpose of the study: to identify predictors of cardiovascular complications and mortality in patients with COVID-19 against the background of acute respiratory distress syndrome.

Materials and Methods: The study included patients with COVID-19 who assessed the onset of symptoms of the disease, health-related quality of life, a physical examination, laboratory tests, and in some patients an assessment of respiratory function and X-ray examination were performed.

Research results. Observation was carried out for 50 patients admitted to the COVID-19 covid hospital in Ferghana. Mean age 56.7±4.6, including 47 men (78.3%), 13 (21.6%) women. The duration of the disease (history from the onset of clinical symptoms to hospitalization) averaged 14.6±2.5 days, the duration of hospitalization ranged from 14 to 27 days (25.5±1.2). Of those included in the study, 57 (95%) had a history of cardiovascular diseases (IHD, AH, CHF, etc.), 46 (92%) had type 2 diabetes mellitus, 26 (52%) were overweight and / or obesity, 2 (4%) had newly diagnosed steroid diabetes.

Conclusions: An infectious disease caused by the SARS-CoV-2 virus (COVID-19) often occurs in patients with various cardiovascular risk factors that can affect the course of the infectious process with the development of acute cardiovascular failure, pulmonary embolism on against the background of acute respiratory distress syndrome due to total damage to the lung tissue with possible additional damage to the heart and blood vessels, contributing to the occurrence of cardiovascular complications and worsening of the prognosis in patients with COVID-19.

Key words: COVID-19, SARS-CoV-2, acute cardiovascular failure, pulmonary embolism, acute respiratory distress syndrome.

First page

99

Last page

107

For citation: Talipova Yu.Sh., Tulaboeva G.M., Sagatova Kh.M. Abdukadirova N.M., Khashimov A.A., Achilov F.K. – PREDICTION OF THE RISK OF FATAL COMPLICATIONS IN ELDERLY PATIENTS WHO SURVIVED COVID-19 //New Day in Medicine 99-107 https://clck.ru/33X5BW

LIST OF REFERENCES:

1. Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H et. al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine & Growth Factor Reviews. 2020; 53:38-42. 
2. World Health Organization. Clinical management of COVID-19. WHO Reference Number: WHO/2019-nCoV/clinical/2020.5. 2020. [Internet] 2020.
3. Министерство здравоохранения РФ. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 7 (03.06.2020). Москва.
4. Tobaiqy M, Qashqary M, Al-Dahery S, Mujallad A, Hershan AA, Kamal MA et al. Therapeutic management of patients with COVID-19: a systematic review. Infection Prevention in Practice. 2020; 100061.
5. Darmon P, Dadoun F, Boullu-Ciocca S, Grino M, Alessi M-C, Dutour A. Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. American Journal of Physiology-Endocrinology and Metabolism. 2006; 291(5): E995-1002. 
6. Zarković M, Beleslin B, Ćirić J, Penezić Z, Stojković M, Trbojević B et. al. Glucocorticoid effect on insulin sensitivity: A time frame. Journal of Endocrinological Investigation. 2008; 31(3):238-42.
7. Clore J, Thurby-Hay L. Glucocorticoid-Induced Hyperglycemia. Endocrine Practice. 2009; 15(5):469-74. 
8. Shono A, Mori S, Nakamura K, Yatomi A, Takada H, Tanaka H et. al. Glucocorticoid-sensitive Paroxysmal Atrial Fibrillation, Sick Sinus Syndrome, and Mitral Regurgitation in a Patient with Malignant Rheumatoid Vasculitis. Internal Medicine (Tokyo, Japan). 2019; 58(21):3093-8. 
9. Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S et. al. Fibrinolysis Shutdown Correlates to Thromboembolic Events in Severe COVID-19 Infection. Journal of the American College of Surgeons. 2020; S1072-7515(20)30400-2.
10. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. 2020; 18(4):844-7. 
11. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. Journal of Thrombosis and Haemostasis. 2020; 18(5):1023-6. 
12. Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units – the experience in Sichuan Province, China. Intensive Care Medicine. 2020; 46(2):357-60. 
13. The OpenSAFELY Collaborative, Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. Epidemiology. 2020.
14. Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nature Reviews Immunology. 2020; 20(5):271-2. 
15. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020; 395(10229):1033-4. 
16. Xu X, Han M, Li T, Sun W, Wang D, Fu B et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020; 117(20):10970-5. 
17. Ucciferri C, Auricchio A, Di Nicola M, Potere N, Abbate A, Cipollone F et al. Canakinumab in a subgroup of patients with COVID-19. The Lancet Rheumatology. 2020;
18. Wan MT, Shin DB, Winthrop KL, Gelfand JM. The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. Journal of the American Academy of Dermatology. 2020; S0190962220308665.
19. Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology. 2020; S0091674920307387.
20. Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARSCoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020; 34(6):1503- 11.